Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.

NCT02611908 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped No participants enrolled

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG: ibrutinib
DRUG: obinutuzumab

Sponsor

Michael Choi

Collaborators

[object Object]